Stifel analyst Daniel Arias raised the firm’s price target on 10x Genomics (TXG) to $25 from $20 and keeps a Buy rating on the shares. Following this week’s AGBT conference in Florida, the firm tells investors that new product adoption for 10x looks “solid” and the competitive environment looks “favorable” within single cell.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $20 from $14 at UBS
- 10x Genomics Earnings Call: Consumables Shine, CapEx Bites
- Risk Factors Weigh on 10X Genomics: Uncertain Guidance, Stock Volatility, and Capital-Raising Challenges
- 10x Genomics price target raised to $17 from $16 at Deutsche Bank
- 10x Genomics price target raised to $19 from $18 at TD Cowen